Canine spinal meningiomas and nerve sheath tumours in 34 dogs (2008‐2016): Distribution and long‐term outcome based upon histopathology and treatment modality

The purpose of this retrospective, multicentre case series was to describe the outcome following surgery and/or radiation of spinal meningiomas and nerve sheath tumours (NSTs) based upon treatment modality, with a specific aim to evaluate the survival times and time to recurrence following treatment...

Full description

Saved in:
Bibliographic Details
Published in:Veterinary & comparative oncology 2018-09, Vol.16 (3), p.344-351
Main Authors: Lacassagne, K., Hearon, K., Berg, J., Séguin, B., Hoyt, L., Byer, B., Selmic, L. E.
Format: Article
Language:English
Subjects:
canine
dogs
meningioma
neoplasia
nerve sheath tumor
spinal cord
survival
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The purpose of this retrospective, multicentre case series was to describe the outcome following surgery and/or radiation of spinal meningiomas and nerve sheath tumours (NSTs) based upon treatment modality, with a specific aim to evaluate the survival times and time to recurrence following treatment for each histopathological diagnosis. Our hypothesis was that the addition of radiation therapy modalities to treatment will yield longer time to recurrence of clinical signs and survival time. Thirty‐four dogs met the inclusion criteria of histopathologically diagnosed extramedullary spinal meningioma or NST. Sixteen extramedullary spinal meningiomas and 18 NSTs were diagnosed. A diagnosis of meningioma was associated with a significantly longer survival time compared with NSTs, with median survival times (MST) of 508 days (95% confidence interval [CI]: 66‐881) vs 187 days (95% CI: 76‐433; P = .02). Dogs (seven) treated with stereotactic radiation therapy (SRT) for recurrence after surgery alone or SRT alone as their initial treatment gained an additional 125 to 346 days survival time.
ISSN:1476-5810
1476-5829
DOI:10.1111/vco.12385